价格

INTERCEPT PHARMACEUTICALS, INC.

ACTIVE

9520 Towne Centre Dr Ste 200, San Diego, New York, 美国www.interceptpharma.comPublic501–1,000 名员工成立于: 2002-01-01

别名:

intercept

ICPT

概览

试验阶段分布

阶段

试验数

占比

1 期

92.9%

2 期

2.4%

试验状态分布

进行中（未招募）

95.2%

已完成

2.4%

招募中

2.4%

药物批准

暂无批准数据

资讯

Stripe, Anthropic, and OpenAI Back $500 Million Intercept Fund to Eliminate Respiratory Viruses

- A new $500 million nonprofit fund called Intercept launched June 24 aims to eliminate respiratory infections like the common cold and flu by de-risking early-stage drug development and deploying air-cleaning technologies. - Backed by Stripe, Anthropic, OpenAI Foundation, Bill Gates, and others, Intercept plans to shepherd at least two drug candidates through Phase I and II clinical trials to attract pharmaceutical industry partners. - The initiative also seeks corporate partners including Warby Parker, Mastercard, and JP Morgan to pilot air filtration and UV light systems in workplaces, treating airborne pathogen removal like municipal water purification. - Scientific advisors include former FDA official Peter Marks and Operation Warp Speed leader Moncef Slaoui, with University of Washington structural biologist David Veesler providing the technical vision for broad-spectrum countermeasures.

Jun 24, 2026

Inventiva Appoints New Leadership Team to Advance MASH Drug Lanifibranor Through Phase 3 Trial

- Inventiva has appointed Dr. Jason Campagna as President of R&D and Chief Medical Officer to lead the development of lanifibranor, a first-in-class pan-PPAR agonist for MASH treatment. - Dr. Campagna brings extensive experience from Intercept, where he led the first-ever NDA submission for MASH indication and designed advanced clinical programs. - Dr. Martine Zimmermann joins as Executive Vice President of Regulatory Affairs and Quality Assurance, bringing expertise in global regulatory strategy for chronic liver diseases. - The appointments come as Inventiva advances lanifibranor through the pivotal Phase 3 NATiV3 trial, with topline results expected in the second half of 2026.

Jul 10, 2025

Intercept's Ocaliva Faces Setback as FDA Advisory Committee Recommends Against Full Approval for PBC

- The FDA's Gastrointestinal Drugs Advisory Committee (GIDAC) has voted against full approval of Intercept's Ocaliva for primary biliary cholangitis (PBC). - The vote raises concerns about Ocaliva's clinical benefit as a second-line therapy for PBC patients, despite eight years of real-world patient experience. - Intercept remains committed to working with the FDA to address concerns and seek full approval for Ocaliva, with a PDUFA date set for October 15, 2024. - Ocaliva, a farnesoid X receptor (FXR) agonist, is currently approved under accelerated approval based on reduction in alkaline phosphatase (ALP).

Sep 14, 2024

返回机构列表

INTERCEPT PHARMACEUTICALS, INC.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（42）

The purpose of this trial is to assess dose related safety, early efficacy, pharmacokinetics and pharmacodynamics of INT-787 in patients with severe alcohol-associated hepatitis (sAH).

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.

Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as PBC).

Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as Primary Biliary Cirrhosis or PBC).

Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as Primary Biliary Cirrhosis or PBC).

Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as Primary Biliary Cirrhosis or PBC).

Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as PBC).

Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as PBC).

药物批准

资讯

Stripe, Anthropic, and OpenAI Back $500 Million Intercept Fund to Eliminate Respiratory Viruses

Inventiva Appoints New Leadership Team to Advance MASH Drug Lanifibranor Through Phase 3 Trial

Intercept's Ocaliva Faces Setback as FDA Advisory Committee Recommends Against Full Approval for PBC